The growing interest in effective weight management has resulted in considerable investigation into cutting-edge treatments. Recently , Retatrutide, a dual -action glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor activator , has exhibited promising results in clinical trials,